CC10230 / AglaeaPharma, Alpherabio - LARVOL DELTA

Targeting peripheral α2A-adrenoceptors as a dual-benefit approach for integrated cancer therapy and supportive care (AACR 2026) - "These findings establish peripheral α2AAR activation as a promising two-pronged translational strategy for integrated oncology care, simultaneously inhibiting tumor progression and alleviating cancer-related pain while circumventing CNS-mediated side effects. The favorable safety profile of CC10230 supports its potential for sustained antitumor therapy without the tolerability limitations of conventional α2AAR agonists."

Oncology • Osteosarcoma • Sarcoma • Solid Tumor